Considerations in analyzing single-trough concentrations using mixed-effects modeling

被引:18
作者
Booth, BP [1 ]
Gobburu, JVS [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, Off Clin Pharmacol & Biopharmaceut, Div Pharmaceut Evaluat 1, Rockville, MD 20857 USA
关键词
population pharmacokinetics; bias; trough concentrations; Bayesian estimates;
D O I
10.1177/0091270003258670
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of this study was to assess the effect of trial design and data analysis choices on the bias and precision of pharmacokinetic (PK) parameter estimation, NONMEM was used to simulate and analyze plasma concentrations collected according to a dense (five samples) or sparse (single-trough samples) sampling scheme for a one-compartment open model with intravenous administration. The results indicated that the bias on estimates of CL with only single-trough data was 17% compared to less than 1% for only dense data. The estimates of CL were improved by fixing all other parameters and estimating only mean and variance of CL (-11% to 1.4%, depending on the estimation method). Adding dense data led to further improvements (-2.3% to 0.3%, depending on further improvements). In these cases, first-order conditional estimation (FOCE) methods resulted in better estimates of CL than first-order (FO) methods. These steps also improved the Bayesian estimates of CL. These studies support the following recommendations: (1) avoid collecting single-trough concentrations unless there is reasonable knowledge about the PK of the drug; (2) if collecting single-trough concentrations is inevitable, avoid estimating all parameters when modeling single-trough concentration data; (3) use prior information by modeling the single-trough concentration data along with dense data from other studies; and (4) use Bayes estimates if the PK model and its parameters are known with reasonable certainty.
引用
收藏
页码:1307 / 1315
页数:9
相关论文
共 15 条
[1]   Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies [J].
Aarons, L ;
Balant, LP ;
Mentre, F ;
Rowland, M ;
Steimer, JL ;
Vozeh, S .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 49 (04) :251-254
[2]  
BEAL SL, 2000, THINGS YOU MAY HAVE
[3]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[4]   Use of prior information to stabilize a population data analysis [J].
Gisleskog, PO ;
Karlsson, MO ;
Beal, SL .
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2002, 29 (5-6) :473-505
[5]   Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: Some inferences [J].
Gobburu, JVS ;
Lawrence, J .
PHARMACEUTICAL RESEARCH, 2002, 19 (01) :92-98
[6]   AN EVALUATION OF POPULATION PHARMACOKINETICS IN THERAPEUTIC TRIALS .1. COMPARISON OF METHODOLOGIES [J].
GRASELA, TH ;
ANTAL, EJ ;
TOWNSEND, RJ ;
SMITH, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (06) :605-612
[7]  
HOLFORD NHG, 2002, CLIN PHARMACOL THER, V71, P56
[8]   Comparison of some practical sampling strategies for population pharmacokinetic studies [J].
Jonsson, EN ;
Wade, JR ;
Karlsson, MO .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02) :245-263
[9]  
Kowalski KG, 2001, STAT MED, V20, P75, DOI 10.1002/1097-0258(20010115)20:1<75::AID-SIM602>3.0.CO
[10]  
2-C